Leerink Swann reissued their outperform rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a report released on Wednesday. Leerink Swann also issued estimates for Intellia Therapeutics’ Q4 2018 earnings at ($0.46) EPS.
Other research analysts have also recently issued reports about the company. Wedbush restated an outperform rating and set a $36.00 price target on shares of Intellia Therapeutics in a research note on Thursday. Barclays upped their price target on Intellia Therapeutics from $33.00 to $46.00 and gave the stock an overweight rating in a research note on Wednesday, March 7th. JMP Securities began coverage on Intellia Therapeutics in a research note on Thursday, March 8th. They set an outperform rating on the stock. TheStreet cut Intellia Therapeutics from a c- rating to a d rating in a research note on Thursday, December 14th. Finally, BidaskClub upgraded Intellia Therapeutics from a buy rating to a strong-buy rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Intellia Therapeutics has an average rating of Buy and a consensus price target of $34.83.
Intellia Therapeutics (NASDAQ NTLA) opened at $24.61 on Wednesday. Intellia Therapeutics has a twelve month low of $11.15 and a twelve month high of $35.99. The company has a market capitalization of $1,221.18, a P/E ratio of -13.23 and a beta of 2.42.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Wednesday, March 14th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.16). Intellia Therapeutics had a negative net margin of 258.62% and a negative return on equity of 35.97%. The business had revenue of $6.70 million during the quarter, compared to analyst estimates of $8.84 million. During the same quarter in the prior year, the company posted ($0.31) earnings per share. The company’s revenue was up 19.6% on a year-over-year basis. research analysts expect that Intellia Therapeutics will post -2.25 EPS for the current fiscal year.
In other Intellia Therapeutics news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $26.78, for a total transaction of $14,746,273.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 12.80% of the stock is owned by corporate insiders.
Several institutional investors have recently bought and sold shares of NTLA. Farallon Capital Management LLC purchased a new stake in shares of Intellia Therapeutics during the fourth quarter worth $21,911,000. ARK Investment Management LLC increased its position in shares of Intellia Therapeutics by 269.2% during the fourth quarter. ARK Investment Management LLC now owns 1,375,149 shares of the company’s stock worth $26,430,000 after acquiring an additional 1,002,671 shares during the period. GMT Capital Corp purchased a new stake in shares of Intellia Therapeutics during the third quarter worth $8,214,000. Shellback Capital LP purchased a new stake in shares of Intellia Therapeutics during the fourth quarter worth $2,343,000. Finally, Capital Advisors Inc. OK purchased a new stake in shares of Intellia Therapeutics during the fourth quarter worth $1,946,000. 68.14% of the stock is currently owned by institutional investors and hedge funds.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.